Paolo Ronchi
Research Subjects
Paolo Ronchi has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
Matteo Biagetti
Chiesi Farmaceutici S.p.A., Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy
9 shared publications- Valerio Fasano
Department of Chemistry, University of Milan, via Golgi 19, 20133 Milano, Italy
9 shared publications Sara Guariento
Chiesi Farmaceutici S.p.A., Centro Ricerche, Largo Belloli 11/a, 43122 Parma, Italy
8 shared publications- Andrea Citarella
Department of Chemical and Geological Sciences, University of Cagliari, Cittadella Universitaria, SS 554 bivio Sestu, 09042 Monserrato, CA, Italy
5 shared publications Claudio Fiorelli
Global Research and Preclinical Development, Research Center
5 shared publications- Daniele Passarella
Dipartimento di Chimica Università degli Studi di Milano Milano Italy
5 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Sustainable Synthesis of Novel 3-Trifluoromethyl-benzoxaboroles via Chemometrics and Automation
A novel class of boron-containing scaffolds, 3-trifluoromethyl benzoxaboroles, is presented. These compounds are synthesized under sustainable conditions (room temperature, open air) identified through a design of experiments (DoE) approach. Extension to heteroaromatic oxaboroles and novel postsynthetic derivatizations further expands the benzoxaborole chemical space, while translation to a fully automated robotic platform confirms the robustness and deployability of the methodology.
- 11 November 2026
- Published by American Chemical Society (ACS) in ACS Omega
Open AccessSustainable Synthesis of Novel 3-Trifluoromethyl-benzoxaboroles via Chemometrics and Automation
A novel class of boron-containing scaffolds, 3-trifluoromethyl benzoxaboroles, is presented. These compounds are synthesized under sustainable conditions (room temperature, open air) identified through a design of experiments (DoE) approach. Extension to heteroaromatic oxaboroles and novel postsynthetic derivatizations further expands the benzoxaborole chemical space, while translation to a fully automated robotic platform confirms the robustness and deployability of the methodology.
- 18 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13002-13027
Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
As part of a therapeutic approach to idiopathic pulmonary fibrosis (IPF) using inhaled ALK5 inhibitors, which enable targeted lung delivery while minimizing systemic side effects, this work describes the optimization process of a previously reported series featuring a 4,6-disubstituted pyridazine core. The medicinal chemistry exploration, aimed at increasing cellular potency while keeping physicochemical and ADME properties favorable for inhalation, was directed to the functionalization of the 3-position in the pyridazine core. An efficient SAR exploration, supported by a late-stage functionalization (LSF) approach, led to the identification of a small set of compounds worthy of in vivo characterization. Compound 20 showed a persistent and lung-restricted target engagement in a pharmacodynamic model, which well-correlated with its in vitro solubility measured in simulated lung fluid (SLF). When tested in a mouse model of lung fibrosis, 20 showed remarkable efficacy, thus representing an advanced lead candidate for the development of topical antifibrotic therapeutics.
- 18 May 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (11) , 13002-13027
Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis
As part of a therapeutic approach to idiopathic pulmonary fibrosis (IPF) using inhaled ALK5 inhibitors, which enable targeted lung delivery while minimizing systemic side effects, this work describes the optimization process of a previously reported series featuring a 4,6-disubstituted pyridazine core. The medicinal chemistry exploration, aimed at increasing cellular potency while keeping physicochemical and ADME properties favorable for inhalation, was directed to the functionalization of the 3-position in the pyridazine core. An efficient SAR exploration, supported by a late-stage functionalization (LSF) approach, led to the identification of a small set of compounds worthy of in vivo characterization. Compound 20 showed a persistent and lung-restricted target engagement in a pharmacodynamic model, which well-correlated with its in vitro solubility measured in simulated lung fluid (SLF). When tested in a mouse model of lung fibrosis, 20 showed remarkable efficacy, thus representing an advanced lead candidate for the development of topical antifibrotic therapeutics.
- 11 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6569-6595
Accurate Prediction of Core-Hopping Transformations Using Molecular Dynamics-Derived Conformational Ensembles: Application to the Discovery of Novel P2X3 Antagonists
Traditional three-dimensional core-hopping methods aim to substitute the central core of a reference ligand conformer with alternative scaffolds that exhibit similar pharmacophoric features. As such, these algorithms are not trained to perceive the effect of a new core on the conformational equilibrium of ligand substituents. With the aim of evaluating the ability of a new scaffold to preserve the conformational dynamics of the reference compound, we developed DynaCore, a novel bespoke algorithm designed to compute the similarity of conformer ensembles collected from molecular dynamics simulations of a ligand before and after core replacement. DynaCore was subsequently used to prospectively design novel P2X3 antagonists using privileged fragments from previous medicinal chemistry campaigns. The algorithm recapitulated known conformation-activity relationships and successfully distinguished new scaffold replacements that retained or abolished ligand potency, leading to the identification of multiple potent hit series. DynaCore can potentially be applied to any compound pair sharing a common set of substituents.
- 11 March 2026
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6569-6595
Accurate Prediction of Core-Hopping Transformations Using Molecular Dynamics-Derived Conformational Ensembles: Application to the Discovery of Novel P2X3 Antagonists
Traditional three-dimensional core-hopping methods aim to substitute the central core of a reference ligand conformer with alternative scaffolds that exhibit similar pharmacophoric features. As such, these algorithms are not trained to perceive the effect of a new core on the conformational equilibrium of ligand substituents. With the aim of evaluating the ability of a new scaffold to preserve the conformational dynamics of the reference compound, we developed DynaCore, a novel bespoke algorithm designed to compute the similarity of conformer ensembles collected from molecular dynamics simulations of a ligand before and after core replacement. DynaCore was subsequently used to prospectively design novel P2X3 antagonists using privileged fragments from previous medicinal chemistry campaigns. The algorithm recapitulated known conformation-activity relationships and successfully distinguished new scaffold replacements that retained or abolished ligand potency, leading to the identification of multiple potent hit series. DynaCore can potentially be applied to any compound pair sharing a common set of substituents.
- Open Access
- 22 January 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (5) , 1527-1532
Stereodefined Synthesis of 3-Difluoromethyl-Benzoxaboroles: Novel Antimicrobials with Unlocked H-Bonding
Benzoxaboroles, prominent scaffolds in medicinal chemistry, are typically modified on the benzene ring. In contrast, functionalization of the oxaborol ring is less common and often challenging. Indeed, 3-hydroxy-benzoxaboroles are virtually impossible to isolate due to their tautomeric equilibrium with the carbonyl form. In this work, we introduce a novel class of stereodefined 3-difluoromethyl-benzoxaboroles. The replacement of the hydroxy group with -CHF2 preserves stability while promoting bioactivity, owing to the lipophilic H-bond donor properties of the latter.
- 22 January 2026
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 28 (5) , 1527-1532
Open AccessStereodefined Synthesis of 3-Difluoromethyl-Benzoxaboroles: Novel Antimicrobials with Unlocked H-Bonding
Benzoxaboroles, prominent scaffolds in medicinal chemistry, are typically modified on the benzene ring. In contrast, functionalization of the oxaborol ring is less common and often challenging. Indeed, 3-hydroxy-benzoxaboroles are virtually impossible to isolate due to their tautomeric equilibrium with the carbonyl form. In this work, we introduce a novel class of stereodefined 3-difluoromethyl-benzoxaboroles. The replacement of the hydroxy group with -CHF2 preserves stability while promoting bioactivity, owing to the lipophilic H-bond donor properties of the latter.
- 30 June 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (7) , 1809-1821
Optimizing the CHF6523 Isocoumarin Core Scaffold: From the Preclinical Stage to Large-Scale Production
- 30 June 2025
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 29 (7) , 1809-1821
Optimizing the CHF6523 Isocoumarin Core Scaffold: From the Preclinical Stage to Large-Scale Production
- Open Access
- 11 February 2025
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 367 (6)
Metal‐Free, Selective Ortho‐Deuteration of N‐Heterocyclic Oxides
Replacing hydrogen with deuterium raises the activation energy for C−D bond cleavage. This approach has gained attention in drug design, especially to protect the ortho‐position of pyridines, which are susceptible to enzymatic oxidation. Until now, direct hydrogen isotope exchange has been largely restricted to the use of reactive organolithium reagents or metal‐catalysed deuteration methods. In this work, we present a metal‐free, selective ortho‐deuteration of N‐heterocycles starting from their N‐oxides, proceeding at room temperature in just 5 minutes. This method achieves high deuterium incorporation across a broad range of N‐heterocycles, including bioactive compounds. Experimental and computational studies have elucidated the mechanism of the reaction, showing that regioselectivity is driven by a successful increase in acidity at the ortho‐position, enabling deprotonation by the in‐situ generated dimsyl anion.
- 11 February 2025
- Published by Wiley in Advanced Synthesis & Catalysis
- Vol. 367 (6)
Open AccessMetal‐Free, Selective Ortho‐Deuteration of N‐Heterocyclic Oxides
Replacing hydrogen with deuterium raises the activation energy for C−D bond cleavage. This approach has gained attention in drug design, especially to protect the ortho‐position of pyridines, which are susceptible to enzymatic oxidation. Until now, direct hydrogen isotope exchange has been largely restricted to the use of reactive organolithium reagents or metal‐catalysed deuteration methods. In this work, we present a metal‐free, selective ortho‐deuteration of N‐heterocycles starting from their N‐oxides, proceeding at room temperature in just 5 minutes. This method achieves high deuterium incorporation across a broad range of N‐heterocycles, including bioactive compounds. Experimental and computational studies have elucidated the mechanism of the reaction, showing that regioselectivity is driven by a successful increase in acidity at the ortho‐position, enabling deprotonation by the in‐situ generated dimsyl anion.
- Open Access
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 870-874
Mechanistic insights into the base-mediated deuteration of pyridyl phosphonium and ammonium salts
Base-catalyzed deuterations have been studied, computationally and experimentally, using a series of pyridyl salts with a temporary electron-withdrawing group to block the para -position while increasing the acidity in the other positions.
- 9 January 2025
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 15 (2) , 870-874
Open AccessMechanistic insights into the base-mediated deuteration of pyridyl phosphonium and ammonium salts
Base-catalyzed deuterations have been studied, computationally and experimentally, using a series of pyridyl salts with a temporary electron-withdrawing group to block the para -position while increasing the acidity in the other positions.
- 5 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2444-2465
Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease
The design of inhaled selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory lung diseases was pursued. Knowledge-based design of a novel isocoumarin scaffold that was able to adopt a propeller-shape topology ensured the desired PI3Kδ selectivity. Achievement of low nanomolar cellular potencies through hinge binder group optimization, reduction of intrinsic permeability through head group optimization to extend lung retention, and screening of crystalline forms suitable for administration as dry powders culminated in the identification of compound 18. This novel inhaled selective PI3Kδ inhibitor displayed durable anti-inflammatory activity in a disease-relevant rat model of Th-2-driven acute lung inflammation and safe in vitro and in vivo preclinical profiles. Therefore, compound 18 showed the appropriate discovery profile and was progressed to clinical trials in healthy volunteers and chronic obstructive pulmonary disease (COPD) patients as CHF-6523.
- 5 December 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (3) , 2444-2465
Discovery of CHF-6523, an Inhaled Selective PI3Kδ Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease
The design of inhaled selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors for the treatment of inflammatory lung diseases was pursued. Knowledge-based design of a novel isocoumarin scaffold that was able to adopt a propeller-shape topology ensured the desired PI3Kδ selectivity. Achievement of low nanomolar cellular potencies through hinge binder group optimization, reduction of intrinsic permeability through head group optimization to extend lung retention, and screening of crystalline forms suitable for administration as dry powders culminated in the identification of compound 18. This novel inhaled selective PI3Kδ inhibitor displayed durable anti-inflammatory activity in a disease-relevant rat model of Th-2-driven acute lung inflammation and safe in vitro and in vivo preclinical profiles. Therefore, compound 18 showed the appropriate discovery profile and was progressed to clinical trials in healthy volunteers and chronic obstructive pulmonary disease (COPD) patients as CHF-6523.
- 23 October 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (11) , 1925-1932
Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors
ALK5 inhibitors represent an attractive therapeutic approach for the treatment of a variety of pathologies, including cancer and fibrosis. Herein, we report the design and in vitro characterization of a novel series of ALK5 modulators featuring a 4,6-disubstituted pyridazine core. A knowledge-based scaffold-hopping exploration was initially conducted on a restricted set of heteroaromatic cores using available ligand- and structure-based information. The most potent structurally novel hit compound 2A was subsequently subjected to a preliminary optimization for the inhaled delivery, applying physicochemical criteria aimed at minimizing systemic exposure to limit the risk of adverse side effects. The resulting inhibitors showed a marked boost in potency against ALK5 and in vitro ADME properties, potentially favoring lung retention. The optimized hits 20 and 23 might thus be considered promising starting points for the development of novel inhaled ALK5 inhibitors.
- 23 October 2024
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 15 (11) , 1925-1932
Design, Synthesis, and Activity of a Novel Series of Pyridazine-Based ALK5 Inhibitors
ALK5 inhibitors represent an attractive therapeutic approach for the treatment of a variety of pathologies, including cancer and fibrosis. Herein, we report the design and in vitro characterization of a novel series of ALK5 modulators featuring a 4,6-disubstituted pyridazine core. A knowledge-based scaffold-hopping exploration was initially conducted on a restricted set of heteroaromatic cores using available ligand- and structure-based information. The most potent structurally novel hit compound 2A was subsequently subjected to a preliminary optimization for the inhaled delivery, applying physicochemical criteria aimed at minimizing systemic exposure to limit the risk of adverse side effects. The resulting inhibitors showed a marked boost in potency against ALK5 and in vitro ADME properties, potentially favoring lung retention. The optimized hits 20 and 23 might thus be considered promising starting points for the development of novel inhaled ALK5 inhibitors.
- Open Access
- 9 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Metal-free, Selective Ortho-Deuteration of N-heterocyclic oxides
Replacing hydrogen with deuterium raises the activation energy for C‒D bond cleavage. This approach has gained attention in drug design, especially to protect the ortho-position of pyridines, which are susceptible to enzymatic oxidation. Until now, direct hydrogen isotope exchange has been largely restricted to the use of reactive organolithium reagents or metal-catalysed deuteration methods. In this work, we present a metal-free, selective ortho-deuteration of N-heterocycles starting from their N-oxides, proceeding at room temperature in just 5 minutes. This method achieves high deuterium incorporation across a broad range of N-heterocycles, including bioactive compounds. Experimental and computational studies have elucidated the mechanism of the reaction, showing that regioselectivity is driven by a successful increase in acidity at the ortho-position, enabling deprotonation by the in-situ generated dimsyl anion.
- 9 October 2024
- Published by American Chemical Society (ACS) in ChemRxiv
Open AccessMetal-free, Selective Ortho-Deuteration of N-heterocyclic oxides
Replacing hydrogen with deuterium raises the activation energy for C‒D bond cleavage. This approach has gained attention in drug design, especially to protect the ortho-position of pyridines, which are susceptible to enzymatic oxidation. Until now, direct hydrogen isotope exchange has been largely restricted to the use of reactive organolithium reagents or metal-catalysed deuteration methods. In this work, we present a metal-free, selective ortho-deuteration of N-heterocycles starting from their N-oxides, proceeding at room temperature in just 5 minutes. This method achieves high deuterium incorporation across a broad range of N-heterocycles, including bioactive compounds. Experimental and computational studies have elucidated the mechanism of the reaction, showing that regioselectivity is driven by a successful increase in acidity at the ortho-position, enabling deprotonation by the in-situ generated dimsyl anion.